Transforming patient care through cell and gene therapy

Cell therapy advances highlighted during The ONE Forum 2020

Maintaining business continuity during COVID-19

Lessons learned will have positive impacts beyond the pandemic

A roundup of COVID-19 treatments in development

How COVID-19 is accelerating cell therapy innovation

How CAR-T reimbursement discussions help advance the field

Proposed IPPS rule an encouraging step towards a clearer payment process

Overcoming autologous cell therapy logistics challenges in the age of COVID-19

Experienced team for managed logistics is key

Can cell therapies unlock the COVID-19 mystery?

The promise of MSC therapies to treat deadly manifestations of cytokine storms

How COVID-19 is changing the production of cell therapies

Implementation of contingency plans allows for continued progress in therapy development

Navigating a time-sensitive cell therapy supply chain during the coronavirus outbreak (Updated)

Why established systems and relationships matter

HLA matching could bring more allogeneic cell therapies to market, faster

An expert opinion on HLA matching relevance for allogeneic cell therapies